scholarly journals Mining of ADR And Symptoms for Immediate Patient Treatment

2019 ◽  
pp. 178-182
Author(s):  
R Sai Priya ◽  
R Vidya ◽  
Dr. M. Robinson Joel
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Drug Safety ◽  
High Probability ◽  
Statistical Data ◽  
Critical Issue ◽  
Patient Treatment ◽  
Medical Field ◽  
Key Factor ◽  
Post Marketing

Adverse Drug Reaction is the most critical issue in the medical field. The importance of chemical drug reaction is severe and spreading easily. It causes severe major problem in hospitalization. Here it gives you a detailed view of ADR effects and it mines the data to get instantaneous treatment for the patients. Adverse drug reaction is an cause of harm which affects the patient by taking a medicine. When a person intake a capsule without prescribed by a doctor then it has a high probability of ADR in it. So, it is the important issue in the drug safety. Many ADR are found after post-marketing clinical trials so identifying ADR in pre-marketing trial is more important rather than post trials. Statistical data is the main key factor in mining concept to detect the ADR as early as possible in the drug safety.

Radical embedding combined dynamic embedding based BERT in Bi-LSTM-CRF model for Chinese named entity recognition from Adverse Drug Event records (Preprint)

2020 ◽  
Author(s):  
Hong Wu ◽  
Jiatong Ji ◽  
Haimei Tian ◽  
Yao Chen ◽  
Weihong Ge ◽  
...  
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Information Extraction ◽  
Drug Safety ◽  
Named Entity Recognition ◽  
Entity Recognition ◽  
Named Entity ◽  
Related Information ◽  
Post Marketing ◽  
Radical Model

BACKGROUND With the increasing variety of drugs, the incidence of Adverse Drug Events (ADEs) is increasing year by year. Massive ADEs are recorded in Electronic Medical Records and Adverse Drug Reaction (ADR) reports which are important source of potential ADRs information. OBJECTIVE Meanwhile, it is essential to make latent ADR information to be available automatically for better post-marketing drug safety reevaluation and pharmacovigilance. This present study describes how to identify ADR-related information from Chinese ADE reports. METHODS Our study established an efficient automated tool, named BBC-Radical (BBC-Radical is model that consists of three components – Bidirectional Encoder Representations from Transformers (BERT), Bidirectional Long-Short Term Memory (Bi-LSTM), and Conditional Random Field (CRF)) model to identify ADR-related information from Chinese ADR reports. Token features and radical features of Chinese characters are used to represent the common meaning of a group of words. BERT and Bi-LSTM-CRF were novel models combined these features to conduct Named Entity Recognition (NER) tasks in the free-text section of 24,890 ADR reports of Jiangsu Province Adverse Drug Reaction Monitoring Center from 2010 to 2016. Moreover, the Man-Machine comparison experiment on the ADE records of Drum Tower hospital was designed to compare the NER performance between BBC-Radical model and manual method. RESULTS The NER model achieved relatively high performance of Precision of 96.41%, Recall of 96.03%, and F1 score of 96.22%. It was indicated the performance of the BBC-Radical model (Precision: 87.17%, Recall: 85.69%, and F1 score: 86.43%) is much better than that of the manual method (Precision: 86.1%, Recall: 73.8%, and F1 score: 79.5%) in the recognition task of each kind of entity. CONCLUSIONS The proposed model shows competition in ADR related information extraction from ADE reports and the results suggested that the application of our method in the information extraction of ADR related information is of great significance in improving the quality of ADR reports and post-marketing drug safety evaluation.

scholarly journals Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Zuzaan Zulzaga ◽  
Erdenetuya Myagmarsuren ◽  
Herman J. Woerdenbag ◽  
Eugene P. van Puijenbroek
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Drug Safety ◽  
Reporting System ◽  
Adverse Drug Reaction Reporting ◽  
Safety Data ◽  
Regulatory System ◽  
Basic Structure ◽  
Reaction Reporting ◽  
Adr Reporting

AbstractMonitoring adverse drug reactions is a vital issue to ensure drug safety and to protect the general public from medication-related harmful effects. In order to properly monitor drug safety, a regulatory system needs to be in place as well as an infrastructure that allows for analyzing national and international safety data. In Mongolia, adverse drug reaction (ADR) reporting activities have been implemented in the past decade. During this period, the basic structure and legal basis of an adverse drug reaction monitoring system was established. Because of the fragmented but growing healthcare system and the complexity of pharmaceutical issues in Mongolia, a sustainable process for the development of the adverse drug reaction reporting system is a key issue. The aim of this article is to disclose the Mongolian situation for the rest of the world and to share experiences on how an ADR reporting system can be developed towards a higher and more advanced level to contribute to both national and international drug safety issues. In this article, we review the features of the Mongolian health care and pharmaceutical systems, as well as the current development of the adverse drug reaction reporting system.

scholarly journals Clinical Experience in Germany of Treating Community-Acquired Respiratory Infections with the New 8-Methoxyfluoroquinolone, Moxifloxacin

2001 ◽  
Vol 29 (2) ◽  
pp. 51-60 ◽  
Author(s):  
H Landen ◽  
M Möller ◽  
GS Tillotson ◽  
R Kubin ◽  
G Höffken
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Clinical Practice ◽  
Bacterial Pneumonia ◽  
Respiratory Infections ◽  
Symptom Relief ◽  
Efficacy And Safety ◽  
Community Based ◽  
Acute Exacerbations ◽  
Post Marketing

Moxifloxacin, a new 8-methoxyfluoroquinolone, was evaluated in a large community-based study involving 16 007 patients over a 9-month period. This study was designed as a large post-marketing observational study of the speed, efficacy and tolerability of moxifloxacin when used in clinical practice for the treatment of community-acquired bacterial pneumonia, or acute exacerbations of chronic bronchitis. Physicians and patients were specifically questioned about overall efficacy and safety as well as symptom relief. According to physicians' assessments 96.3% of patients were cured or improved after moxifloxacin treatment. Symptom relief (‘feeling better’) occurred in almost 70% of patients by day 3 and only 2.3% reported an adverse drug reaction. No individual adverse drug reaction was reported at a frequency above 1%. Among the 209 events considered as serious, only 34 were regarded as possibly or probably related to therapy. There were no moxifloxacin-related clinically relevant cases of phototoxicity, hepatotoxicity or cardiotoxicity. Overall, 92.1% of patients considered moxifloxacin to have been beneficial.

scholarly journals Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation

Methods ◽  
2016 ◽  
Vol 110 ◽  
pp. 14-25 ◽  
Author(s):  
Yuxiang Tan ◽  
Yong Hu ◽  
Xiaoxiao Liu ◽  
Zhinan Yin ◽  
Xue-wen Chen ◽  
...  
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Knowledge Discovery ◽  
Drug Safety ◽  
Clinical Implementation

Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective

2008 ◽  
Vol 14 (1) ◽  
pp. 94-105 ◽  
Author(s):  
H.L. Tremlett ◽  
J. Oger
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Case Reports ◽  
Monitoring Program ◽  
The Elderly ◽  
Adr Reporting ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Drug Withdrawals

Adverse drug reaction (ADR) reporting is essential in the post-marketing surveillance of drugs, detection of serious adverse reactions, and has been the basis for drug withdrawals. The study aimed to examine ADR reporting patterns to the multiple sclerosis (MS) immunomodulatory drugs (IMD) in Canada. All ADRs reported to the Canadian ADR Monitoring Program (CADRMP) from 1965 to March 2006 ( n = 193 208) were accessed and ADRs in which an IMD for MS (beta-interferon or glatiramer acetate) was the suspected drug extracted ( n = 888 reports were dated March/96—March/06). Almost half of all IMD ADRs reports (438/888) were sourced through the patient compared to 14.9% (10 649/71 373) of all ADRs reported to CADRMP over the same period. Of IMD ADR reports, 88.7% (788/888) were directed through the manufacturer compared to 57.7% (41197/71373) of all ADRs. Encouragement to others involved in patient care, such as pharmacists, nurses and physicians might enhance reporting of MS ADRs. Despite the limitations of ADR reporting data, previously unpublished case reports in several understudied MS populations were detailed: paediatrics (≤16 years old, n = 4), the elderly (≥65 years, n = 23) and during pregnancy ( n = 12). In addition, 46 deaths suspected by the reporter as being related to IMD treatment were detailed as well as three possible drug interactions. Multiple Sclerosis 2008; 14: 94—105. http://msj.sagepub.com

Sign in / Sign up

Export Citation Format

Share Document